Sponsors (2)
The bill accelerates access to generics and biosimilars and makes petition review more transparent and predictable, but it does so by narrowing when outside parties can raise concerns, increasing compliance burdens on applicants, and creating potential legal risks for petitioners.
Patients with chronic conditions and their doctors could get faster access to lower-cost generics and biosimilars because FDA can dismiss delay-focused petitions and enforce a 60-day filing deadline, speeding competitor entry.
Faster resolution of abusive or serial petitions could reduce regulatory bottlenecks and approval delays, increasing competition and potentially lowering drug prices for patients and reducing costs for taxpayers.
Applicants must disclose petitions and associated time/resources and FDA will have clearer guidance and factors for review, improving transparency and making petition review more predictable for hospitals, health systems, and small drug makers.
Patients, hospitals, and public-interest groups may lose the ability to raise late-arising safety or other significant regulatory concerns after the 60-day deadline, potentially leaving some safety issues unaddressed.
FDA's authority to deny petitions deemed 'primarily to delay' risks inconsistent application and could be used to block legitimate challenges, reducing external oversight of approvals.
Requiring applicants to quantify time/resources and estimate delay shifts administrative and compliance costs onto generic and biosimilar makers, increasing burdens for small manufacturers and health systems.
Based on analysis of 2 sections of legislative text.
Narrows timing and procedures for FDA petitions that seek denial of drug/biologic applications, lets FDA deny delay-motivated or plainly meritless petitions, and requires referral to the FTC.
Official title: To amend subsection (q) of section 505 of the Federal Food, Drug, and Cosmetic Act to clarify the process for denying certain petitions whose primary purpose is to delay the approval of an application submitted under subsection (b)(2) or (j) of such section 505, and for other purposes.
Introduced May 19, 2026 by Eric Sorensen · Last progress May 19, 2026
Changes to FDA petition rules narrow the time and procedures for petitions that seek denial of drug or biologic marketing applications and give FDA new authority to deny or refer petitions the agency determines were filed mainly to delay approvals. It imposes a 60-day deadline for filing such petitions after the petitioner first knew the basis for the petition, requires petitions to be submitted under specific CFR petition provisions (or successors), authorizes FDA guidance listing factors indicating delay-driven filings, permits denial of petitions or supplements that plainly fail to raise valid scientific or regulatory issues, and requires referral of suspected delay-driven filings to the Federal Trade Commission.